Access detailed search options for content from the Clinical Journal of Oncology Nursing & Oncology Nursing Forum below.
Discover what you can learn about breast cancer in our online learning library. Explore resources curated from ONS content and offerings, such as books, courses, clinical practice resources, and articles.
Keep up to date with the latest on our virtual conference and important information from our supporters.
Use these communication techniques with your patients when you need to start palliative care conversations, choose a new treatment plan, or discuss end of life.
Combining a CDK4/6 inhibitor and fulvestrant improves overall survival consistently among patients with hormone receptor–positive, HER2-negative advanced or metastatic breast cancer, according to a U.S. Food and Drug Administration (FDA) analysis. The agency reported the findings in Lancet Oncology.
A protein called AMBRA1 may be to blame for tumor resistance to CDK4/6 inhibitors, according to results from international teams of researchers that were reported in Nature.
Combination treatment with a CDK4/6 inhibitor and aromatase inhibitor (AI) results in similar progression-free survival (PFS) rates in women with hormone receptor-positive, HER2-negative metastatic breast cancer who are aged 70 or older compared to younger women, according to study findings published in the Journal of Clinical Oncology.
Have you had “aha” moments in your life? Times when you finally understood something so completely that you could now fully explain it to someone else? Perhaps you had an aha moment after a session at the recent ONS Congress or after reading an article in the Oncology Nursing Forum or Clinical Journal of Oncology Nursing. Or maybe you finally understood the benefits of dual inhibition of ER+ metastatic breast cancer with antihormonal therapy and CDK4/6 inhibitors after reviewing the recent infographic included with your ONS journal mailing in May.
Ribociclib (Kisqali®) is a CDK 4/6 inhibitor first approved by the U.S. Food and Drug Administration in early 2017 for postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine therapy, based on the MONALEESA trial results.